<DOC>
	<DOCNO>NCT00106119</DOCNO>
	<brief_summary>This study examine two thyroid preparations-levothyroxine ( T4 ) liothyronine ( T3 ) -affect fat cholesterol metabolism , blood sugar regulation , thyrotropin secretion patient thyroid gland remove . Results study may help development good therapy optimize blood sugar cholesterol level patient . Patients 18 year age old thyroid gland remove take long-term thyroid hormone medication may eligible study screening .</brief_summary>
	<brief_title>Thyroid Glucose Energy Metabolism</brief_title>
	<detailed_description>Thyroid hormone action play important role regulation many physiologic process , among glucose lipid metabolism . Interestingly , clinical presentation thyroid dysfunction extremely variable , relatively poor correlation circulate hormone level clinical feature . This finding suggest local , intracellular concentration active hormone liothyronine ( T3 ) , regulate peripheral conversion pro-hormone levothyroxine ( T4 ) , important determinant maintenance thyroidal homeostasis . The aim present study evaluation role peripheral thyroid hormone conversion regulation glucose lipid metabolism assess differential response T4 T3 treatment subject devoid endogenous thyroid hormone production . T3 administration bypass peripheral metabolism therefore allow u assess role peripheral thyroid hormone conversion regulation hormone action end-organ level . Fifty hypothyroid subject initially randomize either thyroid hormone replacement liothyronine ( T3 ) levothyroxine ( T4 ) treatment period ( one arm cross-over design , treatment sequence randomize ) , aim maintain serum TSH level great equal 0.5 less equal 1.5 mU/L , indicate full replacement . After 30-day period steady-state replacement study subject admit Clinical Center , three-day period stabilization overnight fast , undergo follow test : escalate dose TRH stimulation test , indirect calorimetry , grade exercise tolerance test , DEXA scan , echocardiogram . Patients also undergo skeletal muscle biopsy subcutaneous adipose tissue biopsy microdialysis , well two-step euglycemic hyperinsulinemic clamp measurement splanchnic gluconeogenesis . Fasting venous blood sample collect determination parameter lipid , glucose energy metabolism . After discharge , patient switch form thyroid hormone replacement therapy ( second period ) . The therapy adjust order achieve therapeutic goal TSH concentration ( great equal 0.5 less equal 1.5 mU/L ) , analogous achieve first phase study ( TSH le equal 0.5 mU/L difference T3 T4 phase ) . After reach 30-day period steady-state replacement , study subject re-admitted Clinical Center previously describe evaluation procedure repeat .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 year , male female . History total near total thyroidectomy hypothyroidism replacement therapy . For nonthyroidectomized patient , least threeyear history replacement therapy ( least 1.2 mcg/Kg LT4/body weight ) , less 5 % uptake 24H ( 123 ) I thyroid scan replacement therapy . Written informed consent . EXCLUSION CRITERIA : BMI le equal 20 great equal 30 kg/m ( 2 ) . Metastatic thyroid cancer history thyroid cancer high risk recurrence require suppressive thyroid hormone therapy ( Singer 1996 ) . Significant thyroid residual great 1 mL measure ultrasound ( limited thyroidectomized patient ) great 5 percent uptake 24H ( 123 ) I thyroid scan replacement therapy ( limited hypothyroid patient undergone total thyroidectomy ) . History symptom compatible cardiovascular disease , include paroxysmal supraventricular tachycardia , atrial fibrillation , syncopal episode use prescription medication heart condition , include antihypertensive . Allergy lidocaine , isoproterenol , TRH , levothyroxine , liothyronine , Tylenol # 3 , oxycodone , nitroglycerin . Pregnancy unwillingness use nonhormonal contraception study . Breastfeeding Use hormonal contraceptive estrogen replacement therapy . Use tobacco ( smoking , chew ) two week precede hospital admission ( metabolic test ) Diabetes mellitus , either type I II . Hypercholesterolemia ( serum level great equal 240 mg/dL ) , hypertriglyceridemia ( plasma level great equal 220 mg/dL ) and/or use antilipemic therapy . Liver disease ALT serum level great two fold upper laboratory reference limit . Renal insufficiency estimate creatinine clearance less equal 50 mL/min . Use medications/supplements/alternative therapy know alter thyroid function . Current history symptom compatible psychosis include major depression ( include history hospitalization depression , history attempt suicide , history suicidal ideation ) . Use antipsychotic medication History drug alcohol abuse within last 5 year ; current use drug alcohol ( CAGE great 3 ) . Keloid formation ( relative skeletal muscle subcutaneous adipose tissue biopsy ) . Current previous clinically significant ( require medical/surgical intervention ) extrathyroidal manifestation autoimmune thyroid disease ( dermopathy , ophthalmopathy , arthropathy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Levothyroxine</keyword>
	<keyword>Liothyronine</keyword>
	<keyword>Lipid Metabolism</keyword>
	<keyword>Gluconeogensis</keyword>
	<keyword>Thyrotropin Releasing Hormone</keyword>
	<keyword>Deiodinase</keyword>
	<keyword>Replacement Thyroid Hormone Therapy</keyword>
	<keyword>Thyroidectomy</keyword>
	<keyword>Near Total Thyroidectomy</keyword>
</DOC>